Grupo para la caracterización molecular de las neoplasias hematológicas
Hospital del Bierzo
Ponferrada, EspañaHospital del Bierzo-ko ikertzaileekin lankidetzan egindako argitalpenak (5)
2021
-
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 6, pp. 413-420
-
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
Scientific Reports, Vol. 11, Núm. 1
2017
-
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
Leukemia, Vol. 31, Núm. 10, pp. 2094-2103
2009
2008
-
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Blood, Vol. 112, Núm. 10, pp. 4017-4023